Guiding Biologics Product Development From Delivery Preferences
Source: Drug Delivery Leader
In this segment of the Drug Delivery Leader Live online event, Large Molecule Biologics Delivery: Aligning Formulations, Doses, And Devices, Chief Editor Tom von Gunden asks panelist John Higgins about downstream deviceability considerations that would help inform early-stage molecule development. Higgins identifies knowing preferences or goals for route-of-administration (e.g., subcutaneous).
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.
Subscribe to Drug Delivery Leader
X
Subscribe to Drug Delivery Leader